These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 7141370)

  • 1. [Anti-rheumatic therapy in patients with liver diseases. Plasma levels of diclofenac and elimination of diclofenac and metabolites in urine of patients with liver disease].
    Zimmerer J; Tittor W; Degen P
    Fortschr Med; 1982 Sep; 100(36):1683-8. PubMed ID: 7141370
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Experiences with the 14C-aminopyrine breath test in liver cirrhosis and under the effect of sodium diclofenac (Voltaren)].
    Reinicke C; Eitner K; Hippius M; Krombholz B; Stiller KJ; Wächter G
    Dtsch Z Verdau Stoffwechselkr; 1983; 43(3):117-29. PubMed ID: 6603964
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and metabolism of theophylline in patients with liver diseases.
    Staib AH; Schuppan D; Lissner R; Zilly W; von Bomhard G; Richter E
    Int J Clin Pharmacol Ther Toxicol; 1980 Nov; 18(11):500-2. PubMed ID: 7203726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of diclofenac sodium using a developed HPLC method.
    Said SA; Sharaf AA
    Arzneimittelforschung; 1981; 31(12):2089-92. PubMed ID: 7199303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical significance of benzoate-metabolizing capacity in patients with chronic liver disease: pharmacokinetic analysis.
    Yamada S; Yamamoto T; Suou T; Fujii T; Takayama M; Amisaki T; Tabuchi F; Kobayashi J; Hasegawa M; Hoshino U
    Res Commun Chem Pathol Pharmacol; 1992 Apr; 76(1):53-62. PubMed ID: 1518961
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diclofenac sodium: blood concentration of the slow-release form and influence on the metabolism of kallikrein.
    Gross W; Kroh J; Krebs A; Zöller H
    Arzneimittelforschung; 1984; 34(10):1327-9. PubMed ID: 6335038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Caffeine clearance by two point analysis: a measure of liver function in chronic liver disease.
    Wittayalertpanya S; Israsena S; Thamaree S; Tongnopnoua P; Komolmit P
    Tokai J Exp Clin Med; 1996 Dec; 21(4-6):195-201. PubMed ID: 9300980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biotransformation and uric acid lowering effect of benzbromarone in patients with liver cirrhosis - evidence for active benzbromarone metabolites?
    Walter-Sack I; de Vries JX; von Bubnoff A; Pfleilschifter V; Raedsch R
    Eur J Med Res; 1995 Oct; 1(1):16-20. PubMed ID: 9392688
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased thromboxane metabolites excretion in liver cirrhosis.
    Davì G; Ferro D; Basili S; Iuliano L; Camastra C; Giammarresi C; Santarone S; Rocca B; Landolfi R; Ciabattoni G; Cordova C; Violi F
    Thromb Haemost; 1998 Apr; 79(4):747-51. PubMed ID: 9569186
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Magnetic resonance imaging and different levels of iron overload in chronic liver disease.
    Rocchi E; Cassanelli M; Borghi A; Paolillo F; Pradelli M; Casalgrandi G; Burani A; Gallo E
    Hepatology; 1993 Jun; 17(6):997-1002. PubMed ID: 8514272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative determination of sodium-o-[(2,6-dichlorophenyl)-amino]phenylacetate (diclofenac) in human blood plasma or serum.
    Brombacher PJ; Cremers HM; Verheesen PE; Quanjel-Schreurs RA
    Arzneimittelforschung; 1977; 27(8):1597-9. PubMed ID: 303107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic studies on diclofenac sodium in young and old volunteers.
    Willis JV; Kendall MJ
    Scand J Rheumatol Suppl; 1978; (22):36-41. PubMed ID: 278178
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Diagnostic value of the study of caffeine elimination in chronic liver diseases].
    Darnót G; Nemesánszky E; Bariska J
    Orv Hetil; 1995 Apr; 136(18):927-32. PubMed ID: 7739851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of diclofenac sodium (Voltaren) and metabolites in patients with impaired renal function.
    Stierlin H; Faigle JW; Colombi A
    Scand J Rheumatol Suppl; 1978; (22):30-5. PubMed ID: 356243
    [No Abstract]   [Full Text] [Related]  

  • 15. Carnitine metabolism in patients with chronic liver disease.
    Krähenbühl S; Reichen J
    Hepatology; 1997 Jan; 25(1):148-53. PubMed ID: 8985281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors affecting the pharmacokinetics of diclofenac sodium (Voltarol).
    Kendall MJ; Thornhill DP; Willis JV
    Rheumatol Rehabil; 1979; Suppl 2():38-46. PubMed ID: 531447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced external counterpulsation: a new technique to augment renal function in liver cirrhosis.
    Werner D; Trägner P; Wawer A; Porst H; Daniel WG; Gross P
    Nephrol Dial Transplant; 2005 May; 20(5):920-6. PubMed ID: 15788437
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NTP Toxicology and Carcinogenesis Studies of 1-Amino-2,4-Dibromoanthraquinone (CAS No. 81-49-2) in F344/N Rats and B6C3F1 Mice (Feed Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1996 Aug; 383():1-370. PubMed ID: 12692653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amprenavir and ritonavir plasma concentrations in HIV-infected patients treated with fosamprenavir/ritonavir with various degrees of liver impairment.
    Seminari E; De Bona A; Gentilini G; Galli L; Schira G; Gianotti N; Uberti-Foppa C; Soldarini A; Dorigatti F; Lazzarin A; Castagna A
    J Antimicrob Chemother; 2007 Oct; 60(4):831-6. PubMed ID: 17684056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disturbances of iron metabolism in chronic liver diseases.
    Sikorska K; Stalke P; Lakomy EA; Michalska Z; Witczak-Malinowska K; Stolarczyk J
    Med Sci Monit; 2003 Aug; 9 Suppl 3():64-7. PubMed ID: 15156616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.